Gene-Fixed skin patches tested for rare 'Butterfly' disease
NCT ID NCT04186650
First seen Feb 12, 2026 · Last updated Jun 20, 2026 · Updated 20 times
Summary
This trial tests a new approach for recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic condition that causes fragile, blistering skin. Researchers take a small piece of the patient's own skin, fix the faulty gene in a lab, grow it into a larger sheet, and graft it back onto wounds. The study involves 3 adults and focuses on safety and whether the graft helps the skin produce the missing protein.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPIDERMOLYSIS BULLOSA DYSTROPHICA, RECESSIVE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Institut Imagine Necker Hospital
Paris, 75743, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
COL7A1 gene-corrected skin graft
What this could lead to
If successful, this could provide a way to heal large skin wounds in people with RDEB by restoring a missing protein, potentially reducing pain and infection risk.
What could go wrong
This is a very early, small trial with only 3 participants, so results may not apply to everyone. Risks include graft failure, immune reactions, or long-term side effects from the gene therapy.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.